Kaleb Grimes
Family · Cordova, TNNPI 1609599430
Payments from drug & device makers
Across 91 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$368
- AstraZeneca$353
- Lilly USA, LLC$252
- Boehringer Ingelheim$145
- AbbVie$103
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$87
- plus $483 from 13 others
What the payments were for
- Food & beverage$1,791100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 17 | $368 |
| AstraZeneca | 16 | $353 |
| Lilly USA, LLC | 16 | $252 |
| Boehringer Ingelheim | 8 | $145 |
| AbbVie | 4 | $103 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $87 |
| Lundbeck LLC | 4 | $71 |
| Otsuka America Pharmaceutical, Inc. | 3 | $69 |
| Exact Sciences | 4 | $69 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $47 |
| Bayer | 2 | $41 |
| Aimmune Therapeutics, Inc. | 2 | $33 |
| Astellas Pharma US Inc | 1 | $28 |
| Seqirus USA Inc | 1 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $22 |
| Athena Bioscience, LLC | 1 | $19 |
| Ardelyx, Inc. | 1 | $17 |
| GSK | 1 | $16 |
How this compares
$1,791 in reported general payments places this provider in the 75th percentile of 6,706 family providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 119 | $122,313 |
| MounjaroTirzepatide | 88 | $113,679 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 84 | $62,546 |
| JardianceEmpagliflozin | 59 | $57,858 |
| EliquisApixaban | 36 | $38,520 |
| FarxigaDapagliflozin Propanediol | 28 | $23,967 |
| TrulicityDulaglutide | 18 | $20,636 |
| XareltoRivaroxaban | 20 | $18,426 |
| LinzessLinaclotide | 19 | $17,309 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $6,934 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 249 | $5,242 |
| Celecoxib | 26 | $2,608 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 170 | $2,428 |
| Gabapentin | 196 | $2,397 |
| Atorvastatin Calcium | 277 | $2,208 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $252 | $134,314106 claims |
| Novo NordiskOzempic | $368 | $122,313119 claims |
| GSKTrelegy Ellipta | $16 | $62,54684 claims |
| Boehringer IngelheimJardiance | $145 | $57,85859 claims |
| AstraZenecaFarxiga | $353 | $23,96728 claims |
| AbbVieLinzess | $103 | $17,30919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,706 family providers in Tennessee.
Other family in Cordova
- Laura PorchCordova$148K
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.